A Study To Assess the Safety, Tolerability, and Efficacy of Imzokitug in Combination With Pumitamig and Platinum-Doublet Chemotherapy (PDCT) Versus Pumitamig and PDCT as First-line Treatment for Participants With Locally Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC)
← catalyst calendarNCT07680764 · readout in 758 d
Sponsored by Bristol-Myers Squibb (industry) · BMY — their whole pipeline →.
Phase
Phase 2
Status
Recruiting
Study type
Interventional
Design
Randomized · None · Treatment
Enrollment
160estimated
Sites
71
Countries
Argentina, Australia, Brazil +9
Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →
Source: ClinicalTrials.gov, retrieved 2026-08-19
Dates
each axis at the precision it was filed, with the registry's own basis| Date | Filed | Basis | What it is |
|---|---|---|---|
| Start | 2026-08-15 | estimated | When the study began enrolling |
| Primary completion | 2028-09-15 | estimated | The date the last participant is measured for the primary outcome — the readout window |
| Study completion | 2030-09-15 | estimated | The whole study's end, after follow-up |
| First posted | 2026-07-02 | actual | When this record first appeared on the registry |
| Results posted | — | When the sponsor posted results to the registry | |
| Record updated | 2026-07-24 | actual | The sponsor's own last edit to this record — every projection above is as current as this date |
What it studies
Conditions
- Locally Advanced Non-Small Cell Lung Cancer (NSCLC)
- Metastatic Non-Small Cell Lung Cancer (NSCLC)
Interventions
- Drug: Pumitamig — also filed as BMS-986545, BNT327, PM8002
- Drug: Imzokitug — also filed as Anti-CCR8, BMS-986340
Primary outcome
what the primary-completion date above is the date OFObjective response rate (ORR) by investigator (per Response Evaluation Criteria in Solid Tumors (RECIST) v1.1)
measured Up to approximately 4 years
Permalink · BMY's whole pipeline · Catalyst calendar · Every registered study · What changed